publicações selecionadas
- Laboratory variables as predictors of progression in gastroenteropancreatic neuroendocrine tumors in different lines of antineoplastic treatments
- A real-world evidence of immunotherapy adoption in non-small cell lung cancer (NSCLC) treatment and its transition from platinum-refractory to the first line of therapy.
- EP08.02-042 EGFR-TKI +/- Antiangiogenics for EGFR-mutated Advanced NSCLC
- Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System
- Patient-centered outcomes in non-small-cell lung cancer: a real-world perspective
- Análise de custo-efetividade e estratégias para implementar o acesso à terapia anti-EGFR do câncer de pulmão no SUS
- Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
- Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical Trials
- A real-world study of ALK fusion detection, treatment patterns, and survival outcomes of patients with advanced non-small-cell lung cancer (aNSCLC) in Brazil.
- The impact of face-to-face evaluation in the clinical assessment of cancer patients.
- Discrepancies Between the Cost of Advanced Lung Cancer Treatment and How Much Is Reimbursed by the Brazilian Public Healthcare System
- Efficacy and safety of PD-1 inhibitors as first- and second- line treatments for advanced gastroesophageal cancers: A network meta-analysis of phase III clinical trials
- Evidence Strength of Pharmaceutical Industry Funded Clinical Trials in Metastatic Non-Small Cell Lung Cancer: A Comparison with Other Sources of Funding.
- EP04.01-022 Real-world Evidence of Durvalumab for Stage III NSCLC: Survival Outcomes and Patterns of Care Post-progression
- Palliative Prognostic Index accuracy of survival prediction in an inpatient palliative care service at a Brazilian tertiary hospital
- Physical Examination in Medical Oncology Guiding the Development of a Protocol for Teleoncology Care in a Public Health Care Oncology Service
- Association of body mass index (BMI) with clinical efficacy of immune checkpoint inhibitors (ICI) in advanced cancer patients: A retrospective analysis.
- Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma-Renewed Enthusiasm and a Lingering Challenge
- Predictive genetic biomarker in immune checkpoint inhibitor for non-small cell lung cancer: advances and challenges
- Adjuvant therapy for HR+/HER2- early-stage breast cancer (EBC): Changes in practice patterns among community oncologists in Brazil.
- Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario
- Câncer de pulmão: análise de custo-efetividade como uma ferramenta para facilitar o acesso de pacientes do SUS às novas terapias
- Body mass index and immune checkpoint inhibitor efficacy in metastatic cancer patients: A Brazilian retrospective study
- Real-world survival outcomes associated with use of pertuzumab and trastuzumab emtansine (T-DM1) for HER2-positive (HER2+) metastatic breast cancer (MBC) in Brazilian private healthcare setting.
- Maintenance therapy following an anti-EGFR-based induction regimen in metastatic colorectal cancer (mCRC): A network meta-analysis of clinical trials.
- Cost-effectiveness and affordability of anticancer treatment in Brazil
- Challenges and opportunities in building a health economic framework for personalized medicine in oncology
- PP.12 Access to Molecular Testing and Factors to Implement Targeted Therapy in a Brazilian Public Health Service